|
Dr. Caldwell has been with Targacept since its inception. He is responsible for all activities in the Drug Discovery and Development Department, including molecular design, medicinal chemistry, analytical chemistry, pharmaceutical development, process R&D and manufacturing. He is also responsible for Targacept information technology and intellectual property management.
Dr. Caldwell has over 30 years of experience in organic chemistry, focusing on applications of physical and synthetic organic chemistry to mechanisms of pharmacological and toxicological effects of drugs and other xenobiotics. After joining R.J. Reynolds Tobacco Company (RJRT) in 1987 as a research and development chemist, he held positions of increasing responsibility, including senior scientist, senior staff scientist, master scientist, senior manager and head of the Biological Chemistry Division. At RJRT, Dr. Caldwell focused on biochemical toxicology, xenobiotic metabolism and medicinal chemistry, including the development of potential therapeutic agents for the treatment of neurodegenerative diseases and other disorders.
Dr. Caldwell has authored over 80 papers, book chapters and abstracts and holds over 40 pharmaceutical-related patents covering compositions-of-matter and therapeutic applications.
He holds adjunct appointments in the chemistry department of Wake Forest University and in the physiology/pharmacology department at Wake Forest University School of Medicine.
Dr. Caldwell received a B.S. in chemistry from the University of the South (Sewanee, TN) and a Ph.D. in organic chemistry from the University of Wisconsin. | 